logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

Ethical perspectives on pharmacogenomic profiling in the drug development process

delete2002-04-01
delete78
PRE
AI
A
Amalia M. Issa
DOI：10.1038/nrd771delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Pharmacogenomics, which is a field that encompasses the study of genetic polymorphisms that underlie individual differences in drug response, is rapidly advancing. The potential for the widespread use of pharmacogenomics in the drug development process merits an examination of its fundamental impact on clinical-trial design and practice. This article provides a critical analysis of some of the issues that pertain to pharmacogenomics in the drug development process. In particular, four areas will be discussed: clinical-trial design; subject stratification; some new social risks; and economic concerns. Recommendations are offered for addressing the issues that are discussed and anticipating the regulatory needs for pharmacogenomics-based trials.
Keywords:
CLINICAL-TRIALS
HOSPITALIZED-PATIENTS
FUNCTIONAL GENOMICS
ASSOCIATION
POLYMORPHISM
ALPHA-2-MACROGLOBULIN
RECEPTOR
DISEASE
GENES
SCHIZOPHRENIA
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Nature Reviews Drug Discovery cover
Nature Reviews Drug Discovery
IF:
101.8
Papers:
5.1K
Citations:
5.3W

Organization

No organization information available